Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

Abstract In head and neck squamous cell carcinoma (HNSC), chemoresistance is a major reason for poor prognosis. Nevertheless, there is a lack of validated biomarkers to screen for patients for categorical chemotherapy. Fc gamma binding protein (FCGBP) is a mucus protein associated with mucosal epith...

Full description

Bibliographic Details
Main Authors:	Qin Ding, Fengjie Lin, Zongwei Huang, Ying Li, Sunqin Cai, Xin Chen, Hui Liu, Sufang Qiu
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Series:	Scientific Reports
Subjects:	Fc gamma binding protein Paclitaxel resistance Immune infiltration Targeted therapy Head and neck cancer
Online Access:	https://doi.org/10.1038/s41598-024-55210-6

Similar Items

Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma
by: Yu-Hsuan Lin, et al.
Published: (2022-05-01)

Non-coding RNA-mediated high expression of SFXN3 as a prognostic biomarker associated with paclitaxel resistance and immunosuppressive microenvironment in head and neck cancer
by: Kailin Chen, et al.
Published: (2022-09-01)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
by: Juan A. Marín-Jiménez, et al.
Published: (2022-07-01)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
by: Bruno Chauffert, et al.
Published: (2023-01-01)

Paclitaxel-loaded ROS-responsive nanoparticles for head and neck cancer therapy
by: Yaqin Tu, et al.
Published: (2023-12-01)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
by: Shinsuke Suzuki, et al.
Published: (2021-10-01)

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Jordi Rubió-Casadevall, et al.
Published: (2023-08-01)

Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas
by: Görkem Eskiizmir
Published: (2015-09-01)

Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
by: Hideki Tanaka, et al.
Published: (2023-11-01)

Impact of cetuximab plus cisplatin alone and cetuximab plus cisplatin and paclitaxel regimen on humanistic outcome in head and neck cancer
by: Avinash Khadela, et al.
Published: (2023-01-01)

The potential impact of Connexin 43 expression on Bcl-2 protein level and taxane sensitivity in head and neck cancers - in vitro studies
by: Gurbi, Bianka, et al.
Published: (2020)

PES1 is a biomarker of head and neck squamous cell carcinoma and is associated with the tumor microenvironment
by: Yaodong He, et al.
Published: (2023-06-01)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
by: Tomohiro Enokida, et al.
Published: (2020-03-01)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
by: Florencia Veigas, et al.
Published: (2021-03-01)

Study to evaluate the acute toxicities and response to concurrent chemoradiotherapy with weekly cisplatin versus cisplatin and paclitaxel in locally advanced head-and-neck cancer
by: Tony Jacob, et al.
Published: (2023-01-01)

Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma
by: Kun Cui, et al.
Published: (2022-09-01)

Optimization and Evaluation of Poly(lactide-<i>co</i>-glycolide) Nanoparticles for Enhanced Cellular Uptake and Efficacy of Paclitaxel in the Treatment of Head and Neck Cancer
by: Mohamed Haider, et al.
Published: (2020-08-01)

The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers–In Vitro Studies
by: Bianka Gurbi, et al.
Published: (2019-11-01)

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells
by: Marta Celegato, et al.
Published: (2021-12-01)

Metabolism-associated molecular classification and prognosis signature of head and neck squamous cell carcinoma
by: Mengxian Jiang, et al.
Published: (2024-03-01)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
by: Yafan Yang, et al.
Published: (2023-03-01)

Different Forms of TFF3 in the Human Endocervix, including a Complex with IgG Fc Binding Protein (FCGBP), and Further Aspects of the Cervico-Vaginal Innate Immune Barrier
by: Aikaterini Laskou, et al.
Published: (2024-02-01)

Different Molecular Forms of TFF3 in the Human Respiratory Tract: Heterodimerization with IgG Fc Binding Protein (FCGBP) and Proteolytic Cleavage in Bronchial Secretions
by: Jens Weste, et al.
Published: (2022-12-01)

Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
by: Daniele Borsetto, et al.
Published: (2021-02-01)

HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas
by: Jérôme R. Lechien, et al.
Published: (2020-04-01)

Identification of Exosome-Related Genes Associated with Prognosis and Immune Infiltration Features in Head-Neck Squamous Cell Carcinoma
by: Yuanhe You, et al.
Published: (2023-06-01)

Head and neck /
by: Brandwein-Gensler, Margaret
Published: (2010)

DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma
by: Ling-ling Fu, et al.
Published: (2022-07-01)

Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer
by: Muhammad Alamgeer, et al.
Published: (2023-01-01)

Mcminn's color atlas of head and neck anatomy /
by: 394434 Logan, Bari M, et al.
Published: (2010)

Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma
by: Shaokun Liu, et al.
Published: (2024-01-01)

Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma
by: Ling-ling Fu, et al.
Published: (2022-11-01)

Head & neck cancer : current perspectives, advances, and challenges /
by: Radosevich, James A. (James Andrew)
Published: (c201)

Stell & Maran's textbook of head and neck surgery and oncology
by: Watkinson, John C., et al.
Published: (2012)

The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma
by: Lirui He, et al.
Published: (2023-01-01)

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study
by: Pergolizzi Stefano, et al.
Published: (2011-11-01)

Head and neck [electronic resource] /
by: Brandwein-Gensler, Margaret
Published: (2010)

HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma
by: Yan Chen, et al.
Published: (2023-10-01)

Construction and validation of a prognostic nine-gene signature associated with radiosensitivity in head and neck squamous cell carcinoma
by: Congxian Lu, et al.
Published: (2023-11-01)

PLODs: Novel prognostic biomarkers and potential immunotherapy targets for head and neck squamous cell carcinoma
by: Siming Gong, et al.
Published: (2023-02-01)